High-Risk Stage II Colon Cancer After Curative Resection

被引：34

作者：

Sato, Harunobu ^{[1
,2
]}

Maeda, Koutarou ^{[1
,2
]}

Sugihara, Kenichi ^{[1
,3
]}

Mochizuki, Hidetaka ^{[1
,4
]}

Kotake, Kenjiro ^{[1
,5
]}

Teramoto, Tetsuo ^{[1
,6
]}

Kameoka, Shingo ^{[1
,7
]}

Saito, Yukio ^{[1
,8
]}

Takahashi, Keiichi ^{[1
,9
]}

Hirai, Takashi ^{[1
,10
]}

Ohue, Masayuki ^{[1
,11
]}

Shirouzu, Kazuo ^{[1
,12
]}

Sakai, Yoshiharu ^{[11
,13
]}

Watanabe, Toshiaki ^{[1
,14
]}

Hirata, Koichi ^{[1
,15
]}

Hatakeyama, Katsuyoshi ^{[1
,16
]}

机构：

[1] Japanese Study Grp Postoperat Follow Colorectal C, Tokyo, Japan

[2] Fujita Hlth Univ, Sch Med, Dept Surg, Toyoake, Aichi 47011, Japan

[3] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan

[4] Natl Def Med Coll, Dept Surg, Tokyo, Japan

[5] Tochigi Canc Ctr, Dept Surg, Utsunomiya, Tochigi, Japan

[6] Toho Univ, Sch Med, Dept Surg, Tokyo, Japan

[7] Tokyo Womens Med Univ, Sch Med, Dept Surg 2, Tokyo, Japan

[8] Int Med Ctr Japan, Dept Surg, Tokyo, Japan

[9] Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo, Japan

[10] Aichi Canc Ctr, Res Inst, Dept Surg Gastroenterol, Nagoya, Aichi 464, Japan

[11] Osaka Med Ctr Canc & Cardiovas Dis, Dept Surg, Osaka, Japan

[12] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 830, Japan

[13] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan

[14] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan

[15] Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido, Japan

[16] Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, Niigata, Japan

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2011年 / 104卷 / 01期

关键词：

colon carcinoma; curative resection; prognostic factors; adjuvant chemotherapy; SURGICAL ADJUVANT BREAST; COLORECTAL-CANCER; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN; OXALIPLATIN; EFFICACY; THERAPY;

D O I：

10.1002/jso.21914

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: This study was designed to clarify which attributes of stage II colon cancer are associated with tumor recurrence and survival after curative resection, and the effects of adjuvant chemotherapy (ACT). Methods: We retrospectively reviewed outcomes and clinicopathological characteristics of 1476 patients with stage II colon cancer who underwent curative resection. Results: Of 1476 patients, 204 (13.8%) developed recurrence. Macroscopic type, serum CA19-9 levels, venous invasion, emergency operation, and postoperative ileus were independently associated with overall recurrence. Carbohydrate antigen (CA) 19-9 levels, the number of dissected lymph nodes (LN), sex, age, ACT, emergency operation, venous invasion, and macroscopic type were independently associated with poor prognosis. Prognosis was significantly better in patients who received ACT than in those who did not. Among patients with extensive venous invasion, those with fewer than 13 dissected LNs, male patients, and patients >50 years old, the prognosis was significantly better in patients who received ACT than in those who did not. Conclusions: ACT for stage II colon cancer is recommended to improve the prognosis of patients with extensive venous invasion, patients with fewer than 13 dissected LNs, patients >50 years old, and male patients, particularly patients with more than two of these risk factors. J. Surg. Oncol. 2011;104:45-52. (C) 2011 Wiley-Liss, Inc.

引用

页码：45 / 52

页数：8

共 30 条

[1] Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: A multicenter randomized controlled trial [J].